Crizanlizumab - Novartis

Drug Profile

Crizanlizumab - Novartis

Alternative Names: SEG 101; Sel G1

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia

Most Recent Events

  • 19 Dec 2017 Phase-II clinical trials in Sickle cell anaemia (In adults, In the elderly) in USA (IV) (NCT03264989)
  • 11 Dec 2017 Novartis initiates a bridging clinical trial in volunteers before December 2017
  • 04 Aug 2017 Novartis plans a phase II trial for Sickle cell anaemia (In adults, In the elderly) (IV) (NCT03264989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top